Clinical Trials Logo

Psychotic Disorders clinical trials

View clinical trials related to Psychotic Disorders.

Filter by:
  • Withdrawn  
  • Page 1 ·  Next »

NCT ID: NCT05670990 Withdrawn - Depression Clinical Trials

Equine Assisted Services in Children and Adolescents With Mental Illness

EASiCAM
Start date: March 1, 2023
Phase: N/A
Study type: Interventional

Due to an increasing amount of children and adolescents are suffering from mental illnesses i Sweden. Early preventive psychological interventions are important to avoid a long-time use of medicines. Animal assisted therapy and especially equine assisted services (EAS) has shown to be a good complementary method to decrease anxiety and/or depression in children and adolescents. The main aim is to study the effect of a specific EAS program regarding symptoms of mental illness and in long-term follow-up of future healthcare consumption. We will conduct interviews with both participants and their parents besides the questionnaires at follow-ups (12 weeks, and 1 year) The intervention will be EAS at a farm following a detailed program, the staff at the farm are specially trained with a certification to practice EAS. Each session will last for about 60 minutes, once a week. Participants will get information of the study by the child and youth psychiatry in the region of Skane, and from student´s health team at elementary schools. Those who want ti participate will contact the study coordinator for full information and informed consent. The EAS model has been used in treatment of adult with mental illness for many years, and the result are very positive. This project provides an opportunity to evaluate the effect of EAS to promote health and prevent severe manifest mental illness among children and adolescents. There are no previous studies of the long-term effect of EAS regarding health consumption.

NCT ID: NCT05584215 Withdrawn - Psychosis Clinical Trials

Cognitive Behavioural Therapy-Informed Groups for Psychosis

CBTp
Start date: June 3, 2023
Phase: N/A
Study type: Interventional

This is a feasibility study of cognitive behavioural therapy-informed groups for psychiatric inpatients with positive symptoms of psychosis.

NCT ID: NCT05344365 Withdrawn - Clinical trials for Parkinson Disease Psychosis

A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis

Start date: June 2022
Phase: Phase 2
Study type: Interventional

This is an open-label, sequential cohorts, flexible dose study to evaluate the tolerability, safety and pharmacokinetics of iloperidone in elderly patients with Parkinson's disease psychosis (PDP).

NCT ID: NCT05338424 Withdrawn - Schizophrenia Clinical Trials

Exercise Target Brain Oscillations in Psychosis

Start date: July 1, 2022
Phase:
Study type: Observational

Previous studies have shown that cardiorespiratory fitness (how well the heart and lungs are able to function during physical activity) is often reduced in people with psychosis. The goal of this research study is to test the hypothesis that aerobic exercise can lead to small changes in brain functioning that can influence visual perception and attention in psychosis. The type of aerobic exercise used in this study is called Sprint Interval Training, or "SIT". Information from this study will help to develop interventions that enhance cognition and maximize the quality of life for persons living with psychosis. The exercise procedure used is called SIT, which involves training rigorously on a stationary bike for a short period of time followed by a resting period.

NCT ID: NCT05140135 Withdrawn - Schizophrenia Clinical Trials

Effectiveness and Mechanisms of Recovery Oriented Cognitive Therapy

Start date: January 11, 2021
Phase: N/A
Study type: Interventional

This study is evaluating the effectiveness of recovery oriented cognitive therapy (CT-R) for patients with schizophrenia/schizoaffective disorder. To evaluate CT-R, the investigators are conducting a randomized controlled trial with patients from community mental health centers. Participants will be randomized to the CT-R condition, in which the participants will receive approximately 9 months of CT-R as an adjunctive treatment to current medical treatment, or to the continued usual care control condition. The primary outcome measure (positive, negative, and general psychopathology symptoms) as well as secondary measures (quality of life, self-esteem, social anhedonia, recovery, dysfunctional attitudes, resilience, internalized stigma, and hopelessness) will be measured at baseline, 4-5 months after the first therapy appointment, approximately 9 months after the first therapy appointment, and approximately 15 months after the baseline appointment.

NCT ID: NCT04415541 Withdrawn - Psychotic Disorders Clinical Trials

Psychodynamic Psychotherapy for Psychosis

Start date: May 2021
Phase: N/A
Study type: Interventional

The broad goals of our pilot study are to (1) determine whether psychodynamic psychotherapy for psychosis (PPfP), relative to treatment as usual (TaU), can maintain or augment clinical and functional benefits for patients who have achieved initial recovery in our coordinated specialty care (CSC) early psychosis treatment program; (2) to conduct novel empirical study of how various psychodynamic factors may inform candidate selection, mediate therapeutic effects, and influence relational aspects of the therapy; and (3) to conduct a detailed study of how features of therapist and patient speech and behavior influence therapeutic outcomes, therapeutic alliance alliance, and relational process. This registration focuses on the first goal.

NCT ID: NCT04369677 Withdrawn - Psychosis Clinical Trials

Thermoregulation Among Individuals With First-episode Psychosis

Start date: November 1, 2023
Phase:
Study type: Observational

The project will evaluate thermoregulatory processes among individuals with and without first-episode psychosis.

NCT ID: NCT04068857 Withdrawn - Schizophrenia Clinical Trials

Repetitive Transcranial Magnetic Stimulation (rTMS) Self-Referential Processing (rTMS-SRP)

rTMS-SRP
Start date: September 2019
Phase: N/A
Study type: Interventional

This will be a single site pilot study. 16 subjects with early phase psychosis (EPP), defined as medical record documentation of the onset of clinically significant psychotic symptoms within the past ten years, will be randomized 1:1 to double-blind treatment with 5 sessions of rTMS or sham stimulation directed at the bilateral precuneus over the course of 1 week. Subjects will undergo functional magnetic resonance imaging (fMRI) procedures, behavioral and cognitive assessments, and self-referential memory paradigm (SRMP) at baseline and immediately following the final rTMS or sham session. Contact with subjects will be conducted at two weeks after the end of study intervention for adverse event assessments. In the event new adverse events felt to be related to the study intervention have occurred following the termination of study procedures, subjects will be brought in for further safety assessments.

NCT ID: NCT04065360 Withdrawn - Schizophrenia Clinical Trials

Group Cognitive Behavioural Family Intervention (CBFI) for People With Schizophrenia and Their Families

Start date: January 2021
Phase: N/A
Study type: Interventional

Cognitive behavioural family intervention (CBFI) is a brief psychosocial intervention that incorporates the model of cognitive behavioural therapy (CBT) into the family context. It builds upon the current trend of family interventions/psychoeducation with refocusing on the cognitive model within the family interpersonal relationship. Existing literature indicates that CBFI may be effective in improving positive and negative symptoms of people diagnosed with schizophrenia immediately following the programme. This mixed-method is to evaluate the feasibility and effectiveness of a CBFI programme for people with schizophrenia and their families in a local context. The findings may accumulate more evidence that CBFI is a brief and effective psychosocial intervention that is adapted to Hong Kong clinical settings.

NCT ID: NCT04054973 Withdrawn - Schizophrenia Clinical Trials

L-arginine Study for Persistent Symptoms of Schizophrenia

Start date: September 11, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this research is to see if daily combination treatment of L-arginine and Kuvan changes brain chemistry in people experiencing schizophrenia as measured by MRS brain scans.